However, recently, mitogen-activated kinase (MEK) inhibitors have shown impressive efficacy in clinical trials for the treatment of PN with high partial response rates [4,16], resulting in the Food and Drug Administration (FDA) approval of selumetinib in 2020 for the treatment of pediatric patients with PN. The gene discussed is MAP2K7; the disease is poikiloderma with neutropenia.